{"nctId":"NCT00950300","briefTitle":"A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer","startDateStruct":{"date":"2009-10-16","type":"ACTUAL"},"conditions":["Breast Cancer"],"count":596,"armGroups":[{"label":"Herceptin IV + Chemotherapy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: 5-Fluorouracil","Drug: Cyclophosphamide","Drug: Docetaxel","Drug: Epirubicin","Drug: Herceptin IV [trastuzumab]"]},{"label":"Herceptin SC + Chemotherapy","type":"EXPERIMENTAL","interventionNames":["Drug: 5-Fluorouracil","Drug: Cyclophosphamide","Drug: Docetaxel","Drug: Epirubicin","Drug: Herceptin SC [trastuzumab]"]}],"interventions":[{"name":"5-Fluorouracil","otherNames":[]},{"name":"Cyclophosphamide","otherNames":[]},{"name":"Docetaxel","otherNames":[]},{"name":"Epirubicin","otherNames":[]},{"name":"Herceptin IV [trastuzumab]","otherNames":[]},{"name":"Herceptin SC [trastuzumab]","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult women greater than or equal to (≥) 18 years of age\n* Non-metastatic primary invasive adenocarcinoma of the breast clinical stage I to IIIC, including inflammatory and multicentric/multifocal breast cancer, with tumor size ≥1 centimeter (cm) by ultrasound or ≥2 cm by palpation, centrally confirmed HER2-positive (immunohistochemical score \\[IHC\\] 3+ or in situ hybridization \\[ISH\\]-positive)\n* At least 1 measurable lesion in breast or lymph nodes (≥1 cm by ultrasound or ≥2 cm by palpation), except for inflammatory carcinoma (T4d)\n* Baseline left ventricular ejection fraction (LVEF) ≥55%\n* Eastern Cooperative Oncology Group (ECOG) status of 0 or 1\n* Adequate organ function at Baseline\n\nExclusion Criteria:\n\n* History of any prior (ipsilateral and/or contralateral) invasive breast carcinoma\n* Past or current history of malignant neoplasms, except for curatively treated basal and squamous cell carcinoma of the skin and in situ carcinoma of the cervix\n* Metastatic disease\n* Any prior therapy with anthracyclines\n* Prior anti-HER2 therapy or biologic or immunotherapy\n* Serious cardiac illness\n* Pregnant or lactating women","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Observed Serum Trough Concentration (Ctrough) of Trastuzumab Prior to Surgery","description":"Pre-dose samples were obtained prior to surgery (Cycle 8). The observed Ctrough was recorded, averaged among all participants, and expressed in micrograms per milliliter (μg/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.8","spread":"30.3"},{"groupId":"OG001","value":"78.7","spread":"43.9"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Pathological Complete Response (pCR)","description":"Participants were evaluated following eight cycles of treatment and after surgery to assess for pCR, defined as absence of neoplastic invasive cells in the breast according to pathologist examination. The percentage of participants with pCR was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.7","spread":null},{"groupId":"OG001","value":"45.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Observed Ctrough of Trastuzumab After Surgery","description":"Pre-dose samples were obtained after surgery (Cycle 13). The observed Ctrough was recorded, averaged among all participants, and expressed in μg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.1","spread":"37.1"},{"groupId":"OG001","value":"90.4","spread":"41.9"}]}]}]},{"type":"SECONDARY","title":"Predicted Ctrough of Trastuzumab Prior to Surgery","description":"Predicted Ctrough at pre-dose prior to surgery (Cycle 8) was determined on the basis of a population PK model from Study BP22023 (NCT00800436). The mean predicted Ctrough was expressed in μg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.4","spread":"19.4"},{"groupId":"OG001","value":"80.3","spread":"33.2"}]}]}]},{"type":"SECONDARY","title":"Predicted Ctrough of Trastuzumab After Surgery","description":"Predicted Ctrough at pre-dose after surgery (Cycle 13) was determined on the basis of a population PK model from Study BP22023 (NCT00800436). The mean predicted Ctrough was expressed in μg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.7","spread":"20.0"},{"groupId":"OG001","value":"80.6","spread":"33.4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Ctrough of Trastuzumab >20 μg/mL Prior to Surgery","description":"Pre-dose samples were obtained prior to surgery (Cycle 8). The number of participants who had an observed Ctrough \\>20 μg/mL was reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"232","spread":null},{"groupId":"OG001","value":"227","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Ctrough of Trastuzumab >20 μg/mL After Surgery","description":"Pre-dose samples were obtained after surgery (Cycle 13). The number of participants who had an observed Ctrough \\>20 μg/mL was reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"216","spread":null},{"groupId":"OG001","value":"227","spread":null}]}]}]},{"type":"SECONDARY","title":"Maximum Serum Concentration (Cmax) of Trastuzumab Prior to Surgery","description":"PK samples were obtained prior to surgery (Cycle 7). The Cmax during Cycle 7 was recorded, averaged among all participants, and expressed in μg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"221","spread":"118"},{"groupId":"OG001","value":"149","spread":"64.8"}]}]}]},{"type":"SECONDARY","title":"Time of Maximum Serum Concentration (Tmax) of Trastuzumab Prior to Surgery","description":"PK samples were obtained prior to surgery (Cycle 7). The Tmax during Cycle 7 was recorded, averaged among all participants, and expressed in days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.04"},{"groupId":"OG001","value":"4.12","spread":"2.91"}]}]}]},{"type":"SECONDARY","title":"Area Under the Concentration-Time Curve From 0 to 21 Days (AUC21d) of Trastuzumab Prior to Surgery","description":"PK samples were obtained prior to surgery (Cycle 7). Values were extrapolated beyond Day 15 to produce the area over the full 21-day cycle. The AUC21d value at Cycle 7 was calculated from trastuzumab concentration-time profiles using standard non-compartmental PK methods, averaged among all participants, and expressed in days multiplied by micrograms per milliliters (d\\*μg/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2056","spread":"598"},{"groupId":"OG001","value":"2268","spread":"875"}]}]}]},{"type":"SECONDARY","title":"Cmax of Trastuzumab After Surgery","description":"PK samples were obtained after surgery (Cycle 12). The Cmax during Cycle 12 was recorded, averaged among all participants, and expressed in μg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"230","spread":"118"},{"groupId":"OG001","value":"166","spread":"58.8"}]}]}]},{"type":"SECONDARY","title":"Tmax of Trastuzumab After Surgery","description":"PK samples were obtained after surgery (Cycle 12). The Tmax during Cycle 12 was recorded, averaged among all participants, and expressed in days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.13"},{"groupId":"OG001","value":"4.08","spread":"2.87"}]}]}]},{"type":"SECONDARY","title":"AUC21d of Trastuzumab After Surgery","description":"PK samples were obtained after surgery (Cycle 12). Values were extrapolated beyond Day 15 to produce the area over the full 21-day cycle. The AUC21d value at Cycle 12 was calculated from trastuzumab concentration-time profiles using standard non-compartmental PK methods, averaged among all participants, and expressed in d\\*μg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2179","spread":"725"},{"groupId":"OG001","value":"2610","spread":"945"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Total Pathological Complete Response (tpCR)","description":"Participants were evaluated following eight cycles of treatment and after surgery to assess for tpCR, defined as absence of neoplastic invasive cells in the breast and axillary lymph nodes according to pathologist examination. The percentage of participants with tpCR was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.2","spread":null},{"groupId":"OG001","value":"39.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0, Among Those With Measurable Disease at Baseline","description":"Tumor response was assessed using RECIST version 1.0. CR was defined as disappearance of all target lesions and short-axis reduction of any pathological lymph nodes to less than (\\<) 10 millimeters (mm) with no prior assessment of progressive disease (PD). PR was defined as greater than or equal to (≥) 30% decrease from Baseline in sum diameter (SD) of target lesions with no prior assessment of PD. PD was defined as ≥20% relative increase and ≥5 mm of absolute increase in the SD of target lesions, taking as reference the smallest SD recorded since treatment started; or appearance of 1 or more new lesions. The percentage of participants with overall response of CR or PR at the end of neoadjuvant treatment was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.8","spread":null},{"groupId":"OG001","value":"87.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Response According to RECIST Version 1.0, Among Those With Measurable Disease at Baseline","description":"Tumor response was assessed using RECIST version 1.0. CR was defined as disappearance of all target lesions and short-axis reduction of any pathological lymph nodes to \\<10 mm with no prior assessment of PD. PR was defined as ≥30% decrease from Baseline in SD of target lesions with no prior assessment of PD. PD was defined as ≥20% relative increase and ≥5 mm of absolute increase in the SD of target lesions, taking as reference the smallest SD recorded since treatment started; or appearance of 1 or more new lesions. Time to response was defined as the time from first dose of study medication to the first assessment of CR or PR, which was the date the response was first documented by objective evidence, among participants with an overall response of CR or PR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.14","spread":null},{"groupId":"OG001","value":"6.14","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Experienced a Protocol-Defined Event","description":"Protocol-defined events included disease recurrence/progression (local, regional, distant, contralateral) or death from any cause. Imaging was performed at specified visits for up to 5 years after last dose. Thereafter, participants were followed for survival only. The percentage of participants who experienced a protocol-defined event at any time during the study was reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"32.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Event-Free Survival (EFS)","description":"Protocol-defined events included disease recurrence or progression (local, regional, distant, contralateral) or death from any cause. Imaging was performed at specified visits for up to 5 years after last dose. Thereafter, participants were followed for survival only. EFS was estimated by Kaplan-Meier analysis and defined as the time from randomization to the first protocol-defined event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Died","description":"The percentage of participants who died at any time during the study was reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","spread":null},{"groupId":"OG001","value":"13.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was estimated by Kaplan-Meier analysis and defined as the time from randomization to death from any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Anti-Drug Antibodies (ADAs) Against Trastuzumab","description":"Participants provided PK samples for evaluation of anti-trastuzumab antibodies. The number of participants with \"Treatment-induced ADAs\" and \"Treatment-enhanced ADA\" against trastuzumab at any time during or after treatment was reported. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result (four-fold increase of titer).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With ADAs Against Recombinant Human Hyaluronidase (rHuPH20)","description":"Participants in the Herceptin SC arm provided PK samples for evaluation of anti-rHuPH20 antibodies. The number of participants with \"Treatment-induced ADAs\" and \"Treatment-enhanced ADA\" against rHuPH20 (an excipient unique to the SC formulation) at any time during or after treatment was reported. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result (four-fold increase of titer).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":45,"n":298},"commonTop":["Alopecia","Nausea","Neutropenia","Diarrhoea","Asthenia"]}}}